FORMULATION AND IN-VITRO EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF GLIPIZIDE by Timilsina, Sourav et al.
Timilsina et al                                Journal of Drug Delivery & Therapeutics; 2012, 2(5), 4-8    4 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
RESEARCH ARTICLE 
FORMULATION AND IN-VITRO EVALUATION OF SUSTAINED RELEASE MATRIX 
TABLETS OF GLIPIZIDE 
* Timilsina Sourav, Adhikari Angeela, Yadav Arun K, Gupta Nishant K, Shahi Pragya, Shakya Sabin R, 
School of Health and Allied Sciences, Department of Pharmacy, Pokhara University, Kaski, Nepal 
*Corresponding Author’s Email: Saurav2043@hotmail.com 
Received 04 Aug 2012; Review Completed 26 Aug 2012; Accepted 26 Aug 2012, Available online 15 Sep 2012 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Sulfonylurea represents a wide class of drugs used in the 
treatment of diabetes mellitus, compared to other drugs of 
sulfonylurea class; Glipizide has shown to have less 
chances of hypoglycemic shock as an adverse effect. The 
incidence of hypoglycemic symptoms with glipizide GITS 
is low (≤3%)1.  
Relatively high dose of Glipizide makes it a good 
candidate for formulating it as a Sustained release dosage 
form. Glipizide is a second generation sulphonylurea agent 
that is available in a Gastrointestinal Therapeutic System 
(GITS) extended-release formulation. Glipizide GITS 
provides more stable plasma drug concentrations than the 
immediate-release formulation and the once-daily regimen 
may optimize patient compliance. In patients with type 2 
diabetes mellitus, glipizide GITS is at least as effective as 
the immediate-release formulation of glipizide in 
providing glycaemic control, and may have a greater effect 
on fasting plasma glucose levels. Any therapeutic 
advantage over other antidiabetic agent remains to be 
established, but in a preliminary report (n = 40) glipizide 
GITS provided better glycaemic control and produced less 
fasting insulinaemia than glibenclamide1. However from 
manufacturer point of view manufacturing gastrointestinal 
therapeutic system is comparatively more complicated 
process and requires more careful handling and control 
mechanism than formulating matrix tablets. 
So manufacturing GITS is technically challenging for 
developing countries and it also results in increase cost of 
the tablets. Due to this reason matrix system tablet are 
required which require less technology and are cheaper 
compared to GITS1. Hydroxy propyl methyl cellulose is 
the methyl cellulose derivative used as binder in either wet 
or dry granulation. Depending upon the viscosity grades, 
concentration of 2-20% are used for film coating where as 
high viscosity grades may be used to retard the release of 
drugs from a matrix in tablets. 
MATERIALS AND METHODS 
Sustained release glipizide matrix tablets were prepared by 
wet granulation and compression as reported in previous 
report with some modification2. For these matrix systems, 
glipizide, lactose, HPMC (5 cps and 15 cps), PVPK 30, 
magnesium stearate and aerosil were weighed individually. 
Lactose, HPMC and PVPK 30 were passed through sieve 
size 20 and magnesium stearate and aerosil were passed 
through sieve size 60. The drug was suspended in 
methylene chloride (100 ml) and then mixed with lactose 
slowly for uniform adsorption of drug on lactose particles. 
It was dried for 1 hour in open air. The dried granules were 
passed through mesh no 20. These granules were mixed 
with HPMC and PVP K30 in polythene bag for 15 minutes 
and then magnesium stearate and aerosil were finally 
added. Then it was compressed adjusting final weight of 
tablet equal to 600 mg.  
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matrix tablets were prepared by wet granulation and compression of hydroxypropylmethyl cellulose (5 cps and 15 cps), drug 
and other excipients mixture. The promising formulation was compared with the marketed sample of suatained release glynase 
in terms of release pattern. The release rate of a glipizide from matrix tablet was decreased with increasing the concentration as 
well as viscosity polymer. This might be probably due to increased swelling and reduced erosion rate of matrix tablet. The 
formulation 13 (F13) showed the similar result as marketed sample of sustained release glynase tablets in terms of release rate. 
Key Words: Glipizide, Hydroxy propyl methyl cellulose (HPMC), Viscosity grades 
 
Timilsina et al                                Journal of Drug Delivery & Therapeutics; 2012, 2(5), 4-8    5 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
Method of analysis 
Standard preparation 
100 mg of reference standard were weighed and dissolved 
in 100 ml of 0.1 NaOH to make the concentration of 1 
mg/ml. Serial dilution was done to make the final 
concentration of 0.01mg/ml.2 
Sample preparation 
10 ml of the samples were withdrawn at the time interval 
of 0.5 hr, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr. The 
samples withdrawn were replaced by equal amount of 
dissolution medium. 
Dissolution 
The release of glipizide from sustained release formulation 
was studied using Elecrolab dissolution apparatus.2 For 
each test, six formulation was placed in the flask 
containing 900 ml 0.1 M NaOH, dissolution medium2, at 
37±2°C at 50 rpm2. Ten ml aliquot of the medium was 
sampled at pre-determined time of 8 hours. The sample 
was filtered and the concentration of glipizide was 
determined by measuring ultraviolet absorption at 276 
nm3. The mean of six determinants was used to calculate 
drug release from each formulation. 
Table 1: Different formulations with varying HPMC 5cps and 15 cps grade. 
Formulation Drug       (mg) HPMC 5cps (mg) HPMC 15cps (mg) Lactose (mg) 
F1 10 - - 575.6 
F2 10 - 120 455.6 
F3 10 - 180 395.6 
F4 10 - 240 335.6 
F5 10 - 360 215.6 
F6 10 420 - 155.6 
F7 10 480 - 95.6 
F8 10 - 480 95.6 
F9 10 - 420 155.6 
F10 10 140 280 155.6 
F11 10 160 320 95.6 
F12 with PVP 10 240 240 95.6 
F13 with PVP 10 - 480 71.6 
F14 with PVP 10 - 300 251.6 
F15 with PVP 10 - 360 191.6 
F16 with PVP 10 140 280 131.6 
F17 with PVP 10 160 320 71.6 
In the formulation F12-F17, PVP K30 was added and the amount used was 4% of total mass of each tablet. The amount of Magnesium Sterate and 
Colloidal Silicon dioxide (Aerosil) was fixed at 2% and 0.4% respectively for total weight of each tablet.  
RESULTS AND DISCUSSIONS 
The release percentage of the glipizide drug from the 
formulation was studied by changing the viscosity grade as 
well as the mass of the polymer in the tablet matrix. 
Friability, hardness and weight variation results are also 
compared with variation in polymers used. The 
compression pressure was adjusted in such a way that it 
passes the physical parameters. As the physical parameter 
was passed, then dissolution test was carried out for each 
formulation. Firstly, the dissolution test of the formulations 
containing 20%, 30% and 40% HPMC were carried out. 
The dissolution of these concentrations did not give the 
desired result showing the release percentage of 83% to 
94% within half hour as shown in table 4. So the mass of 
HPMC was increased according to Handbook of 
Excipients which states that concentration of HPMC can 
be increased within the range of 20%-80%. The data 
shown in Table 5 suggests that increasing the 
concentration of HPMC within the range 60%-80%, the 
release rate of the glipizide is decreased but it did not meet 
the desired objective of our research. Table 2 shows that 
increasing the HPMC up to maximum limit caused the 
failure in result of friability and hardness. To improve the 
hardness of a tablet in a formulation containing higher 
concentration of HPMC, PVP K30 (Polyvinyl Pyrrolodine 
K 30) as binder was added. The fixed quantity of binder 
used in these formulations had shown the desirable effect 
as shown in Table 7 and 8. Similarly, the dissolution test of 
the marketed sample (Glynase SR) was also carried out as 
illustrated in Table 9. The release percentage and pattern 
of the glipizide in marketed sample and F13 is nearly 
same.  
Table 2: Drug release percentage from formulations containing 20%, 30% and 40% HPMC 15 cps (Without PVP), n=3 F2, 
F3 and F4 had shown the complete release within 0.5 hour. 
Formulation Drug release % 
F1 0.5 hr 1 hr 2 hr 3 hr 4 hr 5 hr 6 hr 7 hr 8 hr 
F2 94% - - - - - - - - 
F3 99.5% -           -           - - - - - - 
F4 83% -           -           -           -           -           -           -           -           
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Table 3: Drug release percentage from formulation containing 60%, 70% and 80% HPMC (Without PVP) 
Formulation                                         Drug release % 
 0.5 hr 1 hr 2 hr 3 hr 4 hr 5 hr 6 
hr 
7 
hr 
8 
hr 
F5 35.8% 56.14% 102% - - - - - - 
 
F6  
F7 
F8 
F9 
42.01% 
33.01% 
25.13% 
29.13% 
91.27% 
67.32% 
43.23% 
42.62% 
   - 
101.26% 
68.11% 
64.12% 
- 
- 
77.06% 
76.29% 
- 
- 
89.32% 
92.11% 
- 
- 
98.26% 
104.11% 
-     
-     
-      
- 
- 
- 
- 
- 
- 
- 
- 
- 
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Figure 1: Drug release percentage from formulation containing 60%, 70% and 80% HPMC (Without PVP) 
With the increase in mass of HPMC to 60%, 70% and 80% of total mass of formulation, the release percentage of glipizide 
is reduced. F8 and F9 had shown the release rate up to 5 hours. 
Table 4: Drug release percentage from formulation containing HPMC 5 cps and 15 cps in 1:2 ratio (Without PVP) 
Formulation Drug release % 
 0.5 hr 1 hr 2 hr 3 hr 4 hr 5 hr 6 hr 7 hr 8 hr 
F10 
 
F11 
24.26% 
 
20.11% 
32.14% 
 
28.25% 
44.18% 
 
37.12% 
68.18% 
 
59.25% 
82.13% 
 
79.22% 
102.13%        
 
98.56% 
-
 
- 
 -         
 
-        
- 
 
- 
 
Drug release percentage from formulation containing HPMC 5 
cps and 15 cps in 1:2 ratio (Without PVP)
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Figure 2: Drug release percentage from formulation containing HPMC 5 cps and 15 cps in 1:2 ratio (Without PVP) 
F10 and F11 contain the formulations of HPMC 5 cps and 15 cps in the ratio 1:2. These formulations had shown the 
complete release within 5 hours. 
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Table 5: Drug release percentage from formulations containing 70% and 80% HPMC i.e. 5 cps and 15 cps in the ratio 1:2 
(with PVP K30) in the formulation F16 and F17 whereas 1:1 in that of F12 
Formulation Drug release % 
 
F12 
 
F 16 
 
F 17 
0.5 hr 
19.94% 
 
22.7% 
 
16.9% 
1 hr 
29.71% 
 
27.62% 
 
27.55% 
2 hr 
39.18% 
 
41.08% 
 
36.08% 
3 hr 
47.07% 
 
50.29% 
 
45.35% 
4 hr 
55.74% 
 
66.83% 
 
53.43% 
5 hr 
66.79% 
 
72.99% 
 
68.61% 
6 hr 
75.07% 
 
87.57% 
 
74.33% 
7 hr 
98.35% 
 
96.25% 
 
90.88% 
8 hr 
- 
 
- 
 
- 
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Figure 3: Drug release percentage from formulations containing 70% and 80% HPMC i.e. 5 cps and 15 cps in the ratio 1:2 
in F16 and F17 and 1:1 in F12 (with PVP K30) which increased the binding property. These formulations showed the 
release rate upto 7 hours. 
Table 6: Drug release percentage from formulation containing 80%, 50% and 60% HPMC 15 cps (With PVP), n=3 
Formulation Drug release % 
 
 
F13 
 
F 14 
 
F 15 
0.5 hr 
 
13.62% 
 
31.42% 
 
24.10% 
1 hr 
 
23.47% 
 
63.08% 
 
33.42% 
2 hr 
 
34.46% 
 
98% 
 
42.62% 
3 hr 
 
37.64% 
 
- 
 
54.63% 
4 hr 
 
57.09% 
 
- 
 
93.25% 
5 hr 
 
64.19% 
 
- 
 
- 
6 hr 
 
71.84% 
 
- 
 
- 
7 hr 
 
80.22% 
 
- 
 
- 
8 hr 
 
87.47% 
 
- 
 
- 
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Figure 4: Drug release percentage from formulation containing 80%, 50% and 60% HPMC 15 cps (With PVP) 
F13, F14 and F15 are the formulations containing 80%, 50% and 60% HPMC respectively. Out of these formulations, F13 showed the 
release rate up to 8 hours. 
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Table 7: Drug release percentage of glipizide shown by dissolution of marketed sample (Glynase SR) 
Formulation Drug release % 
 
Glynase SR 
0.5 hr 
21.60% 
1 hr` 
30.89% 
2 hr 
34.88% 
3 hr 
38.85% 
4 hr 
56.03% 
5 hr 
62.75% 
6 hr 
71.86% 
7 hr 
78.91% 
8 hr 
90.42% 
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Figure 5: Comparison of drug release percentage of marketed sample (Glynase SR) and 80% HPMC 15 cps 
Comparision of drug release percentage with HPMC in different 
concentration and ratio
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Figure 6: Comparison of drug release percentage with HPMC in different concentration and ratio. Comparing F12, F13, 
F16, F17 and Glynase SR, the F13 showed the similar release pattern and percentage of drug as marketed sample. 
CONCLUSION 
Different formulations of sustained release tablets of 
glipizide were prepared by wet granulation method using 
different grade of HPMC. Increasing the amount of HPMC 
resulted in decreasing the release rate of glipizide drug. 
The mass of HPMC as well as viscosity grade plays the 
crucial role in the release of glipizide from the 
formulation. The in vitro analysis of the different 
formulation performed shows that the F13 achieved the 
objective of developing sustained release formulation. 
Hence, future studies of this formulation are recommended 
to prove its efficacy in in vitro and in vivo.  
The advantage of such formulation is that it is cheaper and 
do not require expensive equipments for manufacture than 
other sustain release formulation of glipizide like osmotic 
pump dosage form. 
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